Eli Lilly backs health-tech startup Abridge to expand clinical trial recruitment

Eli Lilly’s venture arm has made an investment in Abridge, a health‑technology company that is moving into the clinical trial recruitment space.

The funding is intended to help Abridge broaden its services within the life‑sciences sector and support the recruitment of participants for pharmaceutical studies.

By partnering with Abridge, Lilly aims to improve trial enrollment efficiency, which could accelerate development timelines for its pipeline.